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Exocrine Pancreatic Insufficiency,
Dyserythropoeitic Anemia, and Calvarial Hyperostosis
Are Caused by a Mutation in the COX4I2 Gene
Eyal Shteyer,1,2,5 Ann Saada,1,5 Avraham Shaag,1 Fida’ Aziz Al-Hijawi,4 Rojette Kidess,3
Shoshanah Revel-Vilk,3 and Orly Elpeleg1,*
Steatorrhea and malabsorption of lipid-soluble vitamins due to exocrine pancreatic insufﬁciency are common in patients with cystic
ﬁbrosis and are predominant in Shwachman-Bodian-Diamond, Pearson, and Johanson-Blizzard syndromes. In four patients who
suffered from congenital exocrine pancreatic insufﬁciency, dyserythropoeitic anemia, and calvarial hyperostosis, we excluded these
disorders and identiﬁed, by using homozygosity mapping, a mutation in the COX4I2 gene. The COX4 protein is an essential structural
subunit of cytochrome c oxidase complex and has two isoforms, encoded by two different genes. We show that the ratio of COX4I2 to
COX4I1 mRNA is relatively high in human acinar cells. The mutation is associated with marked reduction of COX4I2 expression and
with striking attenuation of the physiologic COX4I2 response to hypoxia. Mutation analysis of COX4I2 is warranted in patients with
malabsorption due to exocrine pancreatic insufﬁciency and in patients with dyserythropoeitic anemia.Exocrine pancreatic insufﬁciency (ePI) with failure to
absorb fat is a life-threatening condition. Patients are not
only depleted of fats but may also suffer from coagulop-
athy, rickets, anemia, and corneal disease as a result of deﬁ-
ciency of fat-soluble vitamins. ePI is a common feature of
cystic ﬁbrosis (CF, MIM 219700) and occurs in 95% of
the patients.1 The association of ePI and hematologic
dysfunction is rarer and has been reported in Shwach-
man-Bodian-Diamond syndrome (SBDS, [MIM 260400])
and in Pearson syndrome (PS, [MIM 557000]). In CF and
SBDS, the pancreatic acinar cells are replaced by fat,
whereas in PS the pancreas is atrophic and ﬁbrotic. Hema-
tologic abnormalities are common in patients with SBDS
and PS; in SBDS the bone marrow is hypoplastic and fatty,
and patients suffer from intermittent deﬁciency ofmyeloid
lineages and susceptibility to infections2, whereas in PS
there is typically refractory sideroblastic anemia, which is
usually macrocytic, and the bone marrow has normal
cellularity and distinctive vacuolization.3 PS is caused by
a deletion of mitochondrial DNA (mtDNA), and because
of changing heteroplasmy, the condition may resolve
spontaneously or progress to Kearns-Sayre syndrome
(MIM 530000).4,5
We hereby report a new syndrome characterized by ePI,
dyserythropoietic anemia, and calvarial hyperostosis in
four patients originating from two families of Arab-Muslim
origin. In family A, the parents were ﬁrst cousins, and their
three male offspring, patients 1991, 1990, and 1989, were
affected (Figure 1). The patients were born at term, and
their birth weights were normal (2800–3100 g). Soon after
birth, they presented with steatorrhea, failure to thrive,
and anemia. They had nearly no weight gain over their
birth weight until 4–6 months of age, when supplementa-tion with pancreatic enzymes began. Thereafter, the steat-
orrhea improved, but at 2 years of age their growth param-
eters were still at the third percentile for 6–12 months;
catch-up with their chronological age percentiles occurred
only at about 4 years of age. The hemoglobin levels were
normal at birth but dropped to 5–9 g/100ml at onemonth,
and RBC transfusions were thereafter required at 6–8 week
intervals. After 16–36 months, patients 1990 and 1991
maintained hemoglobin levels of 8–9 g/100 ml, whereas
transfusion frequency increased in patient 1989 concomi-
tantly with the development ofmassive splenomegaly. The
parents noted several episodes of yellowish sclera associ-
ated with mild indirect hyperbilirubinemia. Transfusion
frequency was not inﬂuenced by the administration of
pancreatic enzymes. Additional physical ﬁndings included
distended abdomen with hepatomegaly and progressive
splenomegaly (Figure 2), inguinal and umbilical hernia,
and generalized muscle hypotonia with delayed psycho-
motor development at around 2 years of age but near-
normal development after 4 years of age. The three
brothers each had a large, box-shaped skull with a bony
groove between the frontal and occipital fontanelles, scaly
skin rash over the perineum and 0.2–0.5 cm hyperpig-
mented lesions, bronchial asthma, maldentition, and
severe dental carries.
The fourth patient (1964), a female, was the 11th child of
another, allegedly unrelated, consanguineous family
(family B, Figure 1) living in a neighboring village. One
of her brothers died at 4 months with severe jaundice
and hepatosplenomegaly, and a sister suffered from jaun-
dice and anemia and received monthly transfusions until
her death at 9months. Patient 1964was born at term, birth
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from watery diarrhea, which changed at 2 years to steator-
rhea. Her development was delayed: she started walking at
30 months, and when we ﬁrst saw her, at 3 years old, she
had only 10 words. Her weight and height were at the third
percentile for 12-month-old children. Supplementation
with pancreatic enzymes, along with fat-soluble vitamins,
was then added. Her stools normalized, and within four
months she gained 2 Kg, added 6 cm to her height, turned
more agile, and spoke in short sentences. Her disease
course was otherwise similar to that of family A patients.
Speciﬁcally, at one month her hemoglobin level was 8 g/
100 ml, and she required monthly RBC transfusions at a
hemoglobin level of 6–7.5 g/100 ml. Nonetheless, she had
neither skull hyperostosis nor skin rash.
Blood smears of all four patients showedmoderate aniso-
cytosis and poikilocytosis, mild polychromesia and baso-
philic stippling, and few normoblasts. There was no
cellular debris, acanthocytes, target cells, sickling or spher-
ocytes. The neutrophils had normal segmentation, and the
lymphocytes were well shaped. Platelets had normal size
and color. Ferritin levels were increased, but folic acid,
iron, and TIBC were normal, as was hemoglobin electro-
phoresis. Bone marrow biopsy of patient 1989 at 7 years
of age revealed hypercellular marrowwith trilineage hema-
topoiesis. There was erythroid hyperplasia with megalo-
blastic change and bi- and multi-nucleated red cell precur-
sors but no internuclear chromatin bridges (Figure 3). Iron-
laden macrophages were seen, but there were no ring side-
roblasts.
Serum transaminases, LDH, and bilirubin were slightly
elevated, but gamma-GT, albumin, PT, PTT, cholesterol,
triglycerides, HDL, and creatinine were normal. While
Figure 1. Pedigrees of Families A and B and the Haplotypes
along the Critical Region on Chromosome 20
Patients’ symbols are filled. Numbered symbols represent individ-
uals whose DNA samples were available for analysis. The polymor-
phic microsatellite markers and their chromosomal locations (in
Mb) are given in the upper left panel. C20-22.65M_TAT stands
for hg18_chr20:22654664-22655109. C20-29.67M_CA stands for
hg18_ chr20:29675861-29676305.The Amerpatients were off pancreatic enzymes, vitamin E was low,
and coagulation functions were impaired. Stool elastase
was invariably low (20 mg/g of stool, normal 200–500 mg/g
of stool). An oral glucose-tolerance test performed in
patient 1991 at 6 years of age was normal. Sweat tests
were repeatedly normal.
Plasma lactate levels were always normal, whereas
plasma alanine was slightly increased (peak level
714 mmol/liter, n < 547 umol/liter). Southern blot analysis
of blood mtDNA disclosed a single, 16.5 Kb fragment.
Urinary organic acid analysis and biotinidase activity in
plasma were normal.
Skull x-rays of family A patients revealed abnormally
thickened parietal bones with thinner bones along the sag-
ital suture (Figures 2A and 2B). There were neither signs of
ostepetrosis nor narrowing of the formina, and brain CT
scan did not disclose signs of pressure over the brain. In
a skeletal survey, delayed bone age and osteopenia were
seen. The skull x-rays of the parents in family A disclosed
normal shape and thickness of the calvarial bones.
In all four patients, abdominal ultrasound revealed
enlarged homogeneous liver with normal bile ducts and
portal ﬂow, splenomegaly, and a thickened, granular
pancreas. The abdominal CT scan disclosed pancreatic
atrophy with massive fatty inﬁltration and increased
hepatic density (Figure 2C).
The normal sweat test and the normal size of themtDNA
molecule excluded CF and PS, respectively. Despite the
normal neutrophil count, the hypercellular marrow, and
the lack of skeletal abnormalities, the diagnosis of SBSD
could not be safely excluded at that stage. We therefore
proceeded to homozygosity mapping by using Affymetrix
Human Mapping 50K Array Xba240 as previously
Figure 2. Skull and Abdominal Radiological Findings
(A and B) Patient 1989’s thickened calvarium: (A) Brain CT scan,
axial view; (B) skull x-ray.
(C and D) Abdominal CT scan of patients 1989 (C) and 3041 (D)
disclosing pancreatic atrophy with massive fatty infiltration
(arrows) and increased hepatic density (asterisk).ican Journal of Human Genetics 84, 412–417, March 13, 2009 413
described6 and analyzed the DNA of the four patients. All
experiments involving DNA of the patients, their relatives,
healthy controls, and patients’ cells were approved by the
Hadassah Medical Center Ethical Review Committee. This
analysis revealed two homozygous genomic regions,
shared by the three brothers, on chromosome 20 at
17.12–33.19 Mb and on chromosome 17 at 22.43–28.94
Mb. Of note, the three brothers did not share any homozy-
gous region on chromosomes 7, where the genes for CF
and SBDS reside. Analysis of patient 1964’s DNA sample re-
vealedmultiple genomic regions of homozygosity but only
one region with a haplotype identical to that of the three
brothers.
This region included 210 consecutive SNPs (rs956110-
rs3746427) spanning the 16 Mb on chromosome 20. We
further narrowed it down to 10.45 Mb (20.85–31.3 Mb)
by using polymorphic microsatellite markers (Figure 1).
The multipoint parametric linkage analysis, performed
with SUPERLINK in the two families, gave an LOD score
of ~2 in the region located between markers D20S101
and D20S195. No other genomic region gave positive
LOD scores by linkage analysis, suggesting that chromo-
some 20p11.21-q11.21 contained the responsible gene.
Within this centromeric region there were 117 open
reading frames (ORFs).We have prioritized them according
to their tissue expression (GEO proﬁles), their function (for
example, by searching for proteins involved in RNAmetab-
olism, as is the SBDS gene7), and the phenotypes of mutant
mice. Thus, the sequence of the following genes was deter-
mined, but no mutation was identiﬁed: FOXA2 (MIM
600288), POFUT1 (MIM 607491), ID1 (MIM 600349),
SSTR4 (MIM 182454), NXT1 ([MIM 605811), REM1 (MIM
610388)], XRN2 (MIM 608851), NKX2-2 (MIM 604612),
PAX1 (MIM 167411), NXT1 (MIM 605811), and PLAGL2
(MIM 604866). The sequence of the four coding exons of
the cytochrome c oxidase subunit IV isoform 2 gene
(COX4I2 [MIM 607976]), which is also located within the
deﬁned region, was then determined because this gene
was highly expressed in bone marrow (GEO proﬁles:
GDS1096/212312_at /COX4I2). This resulted in the identi-
ﬁcation of a c.412G > A mutation, changing glutamic acid
at codon 138 to lysine (E138K) (Figure 4). The four patients
were homozygous for the mutation, and their unaffected
relatives were heterozygotes or normal homozygotes
Figure 3. Bone marrow biopsy of
patient 1989. Note multi-nucleated red
cell precursors (solid arrows) and mega-
loblastic changes (dashed arrow)
(Figure 1). However, homozygosity
for the mutation and the surrounding
markers (up until the polymorphic
microsatellite marker D20S101) was
detected in an 8-year-old girl (individual 3041), the ﬁrst
cousin of the mother of patient 1964. This patient was
born at term, and birth weight was 1900 g. At 3 weeks of
age she presented with anemia and subsequently required
blood transfusions monthly. Bone marrow aspiration at 7
months disclosed dyserythropoietic anemia. At 3 years
hepatosplenomegaly became evident, and she underwent
splenectomy at 5 years. Thereafter, she no longer required
blood transfusions, and her hemoglobin level stabilized at
9–10 g/100 ml. Until she was 2 years of age, she failed to
thrive, but her stools were always of normal consistency,
teething and shedding occurred on time, and there were
no signs of coagulopathy. Since early infancy she suffered
from allergic rhinitis and severe asthma and was easily
fatigued. At 8 years of age her weight and height were at
the tenth and 30th percentile, respectively; she had
a box-shaped head with a deep groove along the sagital
suture, but her physical examination was otherwise
normal. Her speech and comprehension were age appro-
priate, but she was doing poorly at school. A skull x-ray dis-
closed hyperostosis of the parietal bones, and an abdom-
inal CT scan revealed pancreatic atrophy with massive
fatty inﬁltration (Figure 2D).
Finally, because the mutation abolished a cleavage site
for the restriction enzyme BsrBI, we screened 90 anony-
mous ethnically matched individuals and 90 anonymous
individuals of Ashkenazi-Jewish origin. None of them
carried the mutation.
Cytochrome c oxidase (COX), the terminal enzyme in
the mitochondrial respiratory chain, catalyzes the reduc-
tion of molecular oxygen by reduced cytochrome c.8 It is
embedded in the mitochondrial inner membrane and is
composed of 13 subunits, ten of which are encoded by
nuclear genes. Only the three mtDNA-encoded subunits
(COI-COIII) form the catalytic core of the enzyme; the
function of the remaining ten subunits is largely
unknown.9 The COX4 protein is a matrix-side polypep-
tide, located at the periphery of the complex. COX4 is
essential for early stages of the COX complex assembly
and becomes rate-limiting when expressed at less than
40% of its normal level.10 Three of the ten nuclear-encoded
polypeptides, subunits IV, VI, and VII, have tissue-speciﬁc
isoforms, each encoded by a separate gene. COX4I1
(MIM 123864) encodes 169 amino acids and is414 The American Journal of Human Genetics 84, 412–417, March 13, 2009
ubiquitously expressed, whereas COX4I2 is mainly ex-
pressed in the lung and encodes 171 amino acids. The
Glu138 residue of COX4I2 protein and the corresponding
residue Glu136 at the COX4I1 protein are highly
conserved at the subunit IV/VIIb interface (Figure 4). The
study of the pathogenicity of this mutation was hampered
by the normal COX activity in the patients’ skin ﬁbroblasts
(data not shown) and by the lack of a COX4 ortholog in
yeast. However, it has been suggested that the transcrip-
tion of COX4 isoforms is regulated by oxygen concentra-
tion; a binding domain for the hypoxia-inducible tran-
scription factor 1 (HIF-1) is found in COX4I2, and it was
proposed that the expression of COX4I2, but not of
COX4I1, is induced by hypoxia.11 We have therefore deter-
mined the mRNA levels of the two COX4 isoforms by
using real-time PCR in the patients’ ﬁbroblasts under phys-
iologic and hypoxic conditions induced by incubation
with 100 uM cobalt chloride for 48 hr. This analysis re-
vealed that COX4I2 expression in the patients’ cells is
reduced to 25% of the control in normoxic conditions
(Table 1). When control ﬁbroblasts were incubated with
cobalt, COX4I2 expression increased 25-fold, whereas in
patients’ cells COX4I2 mRNA level increased by less than
3-fold over the level in normoxic conditions. These ﬁnd-
ings suggest that the E138K mutation interferes with
COX4I2 expression and perturbs COX4I2 response to
hypoxia.
We next hypothesized that the selective nature of the
disease is the result of the difference in the expression
ratio of the two COX4 isoforms in various tissues. Given
the normal glucose tolerance, a high COX4I1/COX4I2
mRNA ratio is expected in the pancreatic islet cells, and
a low ratio is expected in the acinar cells. Because normal
acinar cells were not available, we determined the mRNA
levels of the COX4 isoforms in whole pancreatic tissue
and in pancreatic islet cells. This analysis revealed that
in the whole pancreas the COX4I1/COX4I2 mRNA ratio
Figure 4. The COX4I2 Mutation
(A and B) Genomic fragment of the COX4I2
gene disclosing the c.412 G > A mutation
(arrow) in a patient (A) and an obligate
heterozygote (B).
(C) normal control.
(D) Conservation throughout evolution of
the glutamic acid at codon 138 (bolded).
D. Melano. stands for Drosophila mela-
nogaster.
Table 1. COX4 Isoform mRNA Quantification by Real-Time
PCR
Sample COX4I1/bACT COX4I2/bACT COX4I1/COX4I2
Control fibroblasts 1909.39 0.36 5303.86
Control fibroblasts in
hypoxia
1821.23 8.82 206.49
Patient fibroblasts 1250.43 0.09 13893.67
Patient fibroblasts in
hypoxia
1480.83 0.24 6170.12
Control lymphocytes 655.43 0.24 2730.96
Control pancreas 1245.76 119.41 10.43
Control pancreatic islets 738.89 1.08 684.16
Human pancreatic tissue was obtained from a pathologically proven tumor-
free edge during subtotal pancreatectomy.
is >60-fold lower than the ratio in
the pancreatic islets (Table 1).
Because islet cells occupy only 2%
of the pancreatic tissue but the
acinar cells account for ~80% of
the pancreas, the ﬁndings indicate
that the acinar cells are the major source of COX4I2
mRNA in the pancreas, whereas COX4I1 is the predomi-
nant isoform in the islet cells. A defect in COX4I2 would
therefore affect the exocrine but not the endocrine func-
tion of the pancreas.
Isolated COX deﬁciency is manifested by various combi-
nations of brain, myocard, kidney, liver, and skeletal
muscle symptoms, and anemia is a relatively common
ﬁnding.8 More speciﬁcally, mutations in the assembly
factor COX10 (MIM 602125), which participates in the
biosynthesis of COX prosthetic group heme A, were iden-
tiﬁed in patients with multi-system disease, which
includes severe transfusion-dependent macrocytic
anemia12, and acquired sideroblastic anemia was reported
in patients with heteroplasmic COI (MIM 516030) muta-
tions.13 The hematologic ﬁndings in our patients’ bone
marrow were consistent with dyserythropoietic anemia.
Congenital dyserythropoietic anemias (CDAs) are charac-
terized by markedly increased ineffective erythropoiesis
and in many cases morphological abnormalities of eryth-
roblasts.14 In the most common form, CDA2 [MIMThe American Journal of Human Genetics 84, 412–417, March 13, 2009 415
224100), the RBC has a shortened life span, about 10% of
cases require regular transfusions during infancy and early
childhood, and splenomegaly occurs in 65% of cases.
Linkage analysis localized the CDA2 gene to chromosome
20q11.215, in close proximity to the COX4I2 gene. None-
theless, we did not detect a mutation in the coding
sequence of COX4I2 in a patient of Moroccan-Jewish
origin with CDA2.
Although ePI and calvarial hyperostosis have not been
reported in association with other COX-deﬁciency
syndromes, our data suggest that both are caused by the
COX4I2 mutation. COX activity is important for the
bone-resorbing activity of osteoclasts.16 Because hypoxia
is a major stimulator of osteoclast formation and bone
resorption17 and because calvarial osteoclasts are regulated
in a distinctive manner from osteoclasts of long bones, it is
tempting to speculate that the underlying mechanism of
calvarial hyperostosis in our patients is due to COX4I2’s
being the predominant COX4 isoform in calvarial osteo-
clasts.
Heretofore isolated COX deﬁciency was associated with
mutations in the genes encoding the three mtDNA
subunits (COI-COIII), a single nuclear-encoded subunit18,
and several COX assembly factors (reviewed in8,19). The
ﬁnding of COX4I2 dysfunction in patients with ePI, dyser-
ythropoeitic anemia, and calvarial hyperostosis extends
this list and should also be added to the differential diag-
nosis of ePI, currently including CF, SBDS, PS, and Johan-
son-Blizzard syndrome (MIM 243800).20
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